Oncologix Tech, Inc. (OCLG) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oncologix Tech, Inc. (OCLG) trades at $0.0001 with AI Score 42/100 (Grade C). Oncologix Tech, Inc. operates as a diversified medical holding company, providing healthcare services in the United States. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for OCLG: OCLG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OCLG against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OCLG: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Oncologix Tech, Inc. (OCLG) Financial Services Profile
Oncologix Tech, Inc., a diversified medical holding company, provides healthcare services and medical technologies in the United States. With a focus on home care and medical facilities, the company distributes medical equipment and offers personalized treatment plans, facing challenges in a competitive and evolving healthcare landscape. Currently, Oncologix Tech operates with a negative profit margin.
What Is the Investment Thesis for OCLG?
Oncologix Tech, Inc. presents a challenging investment case given its negative profit margin of -83.2% and a market capitalization of $0.00B as of 2026. The company's high beta of 9.58 suggests significant volatility relative to the market. While the company operates in the growing healthcare services and medical technology sectors, its financial performance raises concerns about its long-term sustainability. Potential investors should closely monitor the company's ability to improve its profitability and manage its operational costs. Growth catalysts may include expansion of its home care services and increased adoption of its medical technologies, but these are contingent on effective execution and market demand. The company's lack of dividend yield further reduces its attractiveness to income-seeking investors.
Based on FMP financials and quantitative analysis
OCLG Key Highlights
Market Cap of $0.00B indicates a small company size and potential liquidity challenges.
- P/E Ratio of -0.03 reflects negative earnings, suggesting the company is currently unprofitable.
- Profit Margin of -83.2% highlights significant operational inefficiencies and cost management issues.
- Gross Margin of 20.1% indicates some ability to generate revenue above the cost of goods sold, but this is offset by high operating expenses.
- Beta of 9.58 suggests the stock is highly volatile compared to the market, indicating higher risk.
Who Are OCLG's Competitors?
OCLG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OCLG's Key Strengths?
Diversified service offerings across home care and medical technology.
- Established distribution network for medical equipment.
- Personalized treatment plans and support services.
- Focus on sleep and respiratory therapies.
What Are OCLG's Weaknesses?
Negative profit margin (-83.2%) indicates financial instability.
- High beta (9.58) suggests high stock volatility.
- Small market capitalization ($0.00B) limits access to capital.
- Dependence on a competitive healthcare market.
What Could Drive OCLG Stock Higher?
OCLG catalyst: Expansion of home care services due to the aging population and increasing demand for in-home care.
- Increased adoption of medical technologies in healthcare facilities, driving demand for Oncologix Tech's products.
- Strategic partnerships and acquisitions to expand service offerings and geographic reach.
What Are the Key Risks for OCLG?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from other healthcare providers and medical equipment distributors.
- Regulatory changes and healthcare reforms impacting reimbursement rates and operational costs.
- Economic downturn affecting demand for healthcare services and medical equipment.
- Technological advancements rendering existing products obsolete, requiring continuous innovation.
What Are the Growth Opportunities for OCLG?
- Expansion of Home Care Services: The market for personal home care services is growing due to the aging population and increasing preference for in-home care. Oncologix Tech can capitalize on this trend by expanding its service offerings and geographic reach. The home healthcare market is projected to reach $225 billion by 2027, offering substantial growth potential for companies like Oncologix Tech that can effectively capture market share. Timeline: Ongoing.
- Increased Adoption of Medical Technologies: Oncologix Tech's manufacturing, marketing, and distribution of medical technologies for various healthcare facilities present a significant growth opportunity. As healthcare providers increasingly adopt advanced technologies to improve patient outcomes and efficiency, Oncologix Tech can benefit from increased demand for its products. The global medical device market is expected to reach $600 billion by 2028. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Oncologix Tech can pursue strategic partnerships and acquisitions to expand its service offerings, geographic reach, and customer base. Collaborating with other healthcare providers and acquiring complementary businesses can enhance the company's competitive position and drive growth. The healthcare industry is characterized by consolidation, and strategic M&A activity can create significant value. Timeline: Ongoing.
- Focus on Sleep and Respiratory Therapies: The market for sleep and respiratory therapies is growing due to the increasing prevalence of sleep apnea and other respiratory conditions. Oncologix Tech's distribution and sale of home medical equipment for these therapies, including C-PAP and BiPAP devices, positions it to benefit from this trend. The global sleep apnea devices market is projected to reach $10 billion by 2027. Timeline: Ongoing.
- Personalized Treatment Plans and Support Services: Oncologix Tech's offering of personalized treatment plans, monitoring, and support services can differentiate it from competitors and drive customer loyalty. As healthcare becomes more personalized and patient-centric, companies that can provide tailored solutions and ongoing support will have a competitive advantage. The market for personalized medicine is expected to reach $4 trillion by 2030. Timeline: Ongoing.
What Are OCLG's Competitive Advantages?
- Diversified service offerings across home care and medical technology.
- Established distribution network for medical equipment.
- Personalized treatment plans and support services for customer retention.
What Does OCLG Do?
Founded in 1995 and based in Lafayette, Louisiana, Oncologix Tech, Inc. has evolved from its origins as BestNet Communications Corp., rebranding in January 2007 to focus on healthcare services. The company operates as a diversified medical holding company, providing a range of healthcare services in the United States. Its offerings include personal home care services such as daily living assistance, companionship, homemaker services, Alzheimer's care, home care resource planning, and medical care coordination. Beyond home care, Oncologix Tech manufactures, markets, and distributes medical technologies and products aimed at skilled nursing facilities, acute and critical care facilities, assisted living facilities, hospitals, medical institutions, federal agencies, and the home medical care industry. The company also distributes and sells home medical equipment for sleep and respiratory therapies, offering durable medical equipment to treat obstructive Sleep Apnea, including C-PAP and BiPAP oxygen equipment, and a selection of mask interfaces. Personalized treatment plans, monitoring, and support services are also part of their service portfolio. Oncologix Tech serves a broad spectrum of healthcare providers and patients, reflecting its diversified approach within the medical sector.
What Products and Services Does OCLG Offer?
- Provides personal home care services, including daily living assistance and companionship.
- Offers Alzheimer's care and home care resource planning.
- Manufactures, markets, and distributes medical technologies for healthcare facilities.
- Distributes and sells home medical equipment for sleep and respiratory therapies.
- Supplies durable medical equipment to treat obstructive Sleep Apnea.
- Offers personalized treatment plans, monitoring, and support services.
How Does OCLG Make Money?
- Generates revenue through the provision of personal home care services.
- Earns income from the sale and distribution of medical technologies and equipment.
- Provides personalized treatment plans and support services for recurring revenue.
What Industry Does OCLG Operate In?
Oncologix Tech, Inc. operates within the financial services sector, specifically as a shell company involved in healthcare services and medical technology distribution. The healthcare industry is experiencing growth driven by an aging population and increasing demand for home care and medical equipment. However, the industry is also highly competitive, with numerous players offering similar services and products. Oncologix Tech's success depends on its ability to differentiate itself through superior service, innovative products, and effective cost management. The company's negative profit margin indicates it faces significant challenges in this competitive landscape.
Who Are OCLG's Key Customers?
- Skilled nursing facilities
- Acute and critical care facilities
- Assisted living facilities
- Hospitals and medical institutions
- Federal agencies
- Home medical care industry
- Respiratory and therapy centers
Financial Health
Oncologix Tech, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
OCLG Valuation & Market Position
Relative to its peer group, OCLG's quantitative score of 42/100 is below the peer average of 63/100.
Key Financial Metrics
Return on equity for Oncologix Tech, Inc. stands at 94.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -34.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Oncologix Tech, Inc. operates in the Financial - Conglomerates industry within the Financial Services sector. It is headquartered in Lafayette, US. The company is led by CEO Michael A. Kramarz. OCLG has traded publicly since 1995.
OCLG Financials
Bull Case vs Bear Case
Bull Case
- Diversified service offerings across home care and medical technology.
- Established distribution network for medical equipment.
- Personalized treatment plans and support services.
- Focus on sleep and respiratory therapies.
Bear Case
- Negative profit margin (-83.2%) indicates financial instability.
- High beta (9.58) suggests high stock volatility.
- Small market capitalization ($0.00B) limits access to capital.
- Dependence on a competitive healthcare market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
OCLG Latest News
No recent news available for OCLG.
OCLG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OCLG.
Price Targets
Wall Street price target analysis for OCLG.
OCLG MoonshotScore
What does this score mean?
The MoonshotScore rates OCLG 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Michael A. Kramarz
CEO
Michael A. Kramarz is the CEO of Oncologix Tech, Inc. His background includes managing 191 employees, indicating experience in leadership and operational oversight. Further details about his career history, education, and previous roles are not available in the provided data. However, his current position suggests a strong understanding of the healthcare services and medical technology sectors.
Track Record: Information regarding Michael A. Kramarz's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. Therefore, a comprehensive assessment of his track record cannot be made at this time.
OCLG OTC Market Information
OCLG trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Oncologix Tech, Inc. Financial Services Stock: Key Questions Answered
What does the AI Score mean for OCLG?
OCLG holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Oncologix Tech, Inc. operates as a diversified medical holding company, providing healthcare services in the United States. The company offers a range of services and products, including personal …
What does Oncologix Tech, Inc. do?
Oncologix Tech, Inc. operates as a diversified medical holding company, providing a range of healthcare services and medical technologies. The company offers personal home care services, manufactures and distributes medical technologies for healthcare facilities, and provides home medical equipment for sleep and respiratory therapies.
What are the main risks for OCLG?
The main risks for Oncologix Tech, Inc. include intense competition from other healthcare providers and medical equipment distributors, which could pressure pricing and market share. Regulatory changes and healthcare reforms could impact reimbursement rates and operational costs. An economic downturn could reduce demand for healthcare services and medical equipment. Additionally, technological advancements could render existing products obsolete, requiring continuous innovation and investment in research and development to maintain competitiveness.
What are the key factors to evaluate for OCLG?
Oncologix Tech, Inc. (OCLG) holds an AI score of 42/100 (low). presents a challenging investment case given its negative profit margin of -83.2% and a market capitalization of $0.00B as of 2026. Not financial advice.
How frequently does OCLG data refresh on this page?
OCLG's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OCLG's recent stock price performance?
Oncologix Tech, Inc. (OCLG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified service offerings across home care and medical technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OCLG overvalued or undervalued right now?
Oncologix Tech, Inc. (OCLG) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OCLG before investing?
Before investing in Oncologix Tech, Inc. (OCLG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OCLG to a portfolio?
Key strength of Oncologix Tech, Inc. (OCLG): Diversified service offerings across home care and medical technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited, potentially impacting the accuracy of the analysis.
- AI analysis is pending, indicating that a comprehensive assessment is not yet available.